Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - omalizumabum - poudre et solvant pour solution injectable - praeparatio cryodesiccata: omalizumabum 150 mg, histidini hydrochloridum monohydricum, histidinum, saccharum, polysorbatum 20, pro vitro. solvens: aqua ad iniectabile. - allergisches asthma, chronische spontane urtikaria, nasenpolypen - biotechnologika

Tunisie - français - Ministère de la Santé, Direction de l'inspection Pharmaceutique

roche pharma (schweiz) ag - le tocilizumab - solution injectable - 162 mg/0.9 ml - antineoplasiques et immunomodulateurs - immunosuppresseurs - polyarthrite rhumatoïde(pr). actemra est indiqué pour réduire les signes et les symptômes chez les patients adultes présentant une polyarthrite rhumatoide active modérée à sévère qui n'ont pas suffisamment répondu ou présenté des effets indésirables lors du traitement par le méthotrexate (mtx) ou par d'autres médications synthétiques modifiant le cours de l'affection rhumatismale(disease modifying antirheumatic drugs, dmard) ou inhibant le facteur de nécrose tumorale (tnf). un ralentissement de la progression des lésions structurelles et une amélioration de la capacité fonctionnelle physique ont été démontrés sous traitement combiné avec le méthotrexate (mtx). actemra peut être administré en tant que monothérapie ou en association au méthotrexate et à d'autres dmard usuels.

Cameroun - français - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

roche - le tocilizumab - solution injectable pour perfusion - 20mg/ml

Cameroun - français - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

roche - le tocilizumab - solution injectable pour perfusion - 20mg/ml

Cameroun - français - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

roche - le tocilizumab - solution injectable pour perfusion - 20mg/ml

Union européenne - français - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - autres agents antinéoplasiques - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agents antinéoplasiques - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

roche - tocilizumab - solution à diluer pour perfusion

Union européenne - français - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymphome, cellule du manteau - agents antinéoplasiques - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Union européenne - français - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agents antinéoplasiques - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.